- Home
- SDGR
SDGR
Schrodinger Inc.
as 04-18-2025 1:42pm EST
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $33.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.60 - $28.47 | Next Earning Date: | 04-30-2025 |
| Revenue: | $207,539,000 | Revenue Growth: | -4.21% |
| Revenue Growth (this year): | 24.12% | Revenue Growth (next year): | 18.60% |
Stock Insider Trading Activity of Schrodinger Inc. (SDGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Akinsanya Karen | SDGR | President of R&D, Therapeutics | Apr 14 '25 | Sell | $25.07 | 16,723 | $419,570.35 | 23,970 | |
| Herman Jenny | SDGR | SVP & Controller | Mar 6 '25 | Sell | $21.11 | 666 | $14,059.26 | 27,349 | |
| Porges Geoffrey Craig | SDGR | EVP & CFO | Mar 3 '25 | Sell | $21.76 | 5,491 | $119,484.16 | 27,544 | |
| Tran Yvonne | SDGR | EVP, CLO & CPO | Feb 18 '25 | Sell | $28.00 | 3,902 | $109,256.00 | 11,135 | |
| Lorton Kenneth Patrick | SDGR | EVP, CTO & COO, Software | Feb 11 '25 | Sell | $24.43 | 985 | $24,063.55 | 41,076 | |
| Tran Yvonne | SDGR | EVP, CLO & CPO | Feb 11 '25 | Sell | $24.43 | 828 | $20,228.04 | 11,135 | |
| Herman Jenny | SDGR | SVP & Controller | Feb 11 '25 | Sell | $24.43 | 859 | $20,985.37 | 27,349 | |
| Abel Robert Lorne | SDGR | See Remarks | Feb 10 '25 | Sell | $25.99 | 1,225 | $31,837.75 | 8,115 |
Latest Schrodinger Inc. News
SDGR Breaking Stock News: Dive into SDGR Ticker-Specific Updates for Smart Investing
Business Wire
19 hours ago
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
3 days ago
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued
Argus Research
3 days ago
SDGR: Raising target price to $27.00
Business Wire
5 days ago
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
Zacks
5 days ago
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Argus Research
10 days ago
SDGR: Lowering target price to $19.00
Argus Research
17 days ago
SDGR: Lowering target price to $20.00
Simply Wall St.
23 days ago
Schrödinger (NASDAQ:SDGR) Is In A Good Position To Deliver On Growth Plans
Compare SDGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SDGR Schrodinger Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.